ELRIG w/ Prof Jackie Hunter

Join BenevolentAI’s Board Director, Jackie Hunter, at ELRIG Research & Innovation 2022 for a keynote presentation

There are multiple opportunities to apply artificial intelligence and other advanced technologies to drug discovery to uncover novel insights, enhance understanding and augment scientific decision making, in order to ultimately increase efficiency and increase the chance of success. In this talk, Jackie Hunter will chart the progress of AI in drug discovery from promise to reality, by providing examples from BenevolentAI's in-house drug pipeline and its partnerships with pharma companies. She will also show how AI can impact the whole value chain via a case study from Brainomix, where she also serves as Board Director.

Register here →

Jackie Hunter

Board Director of BenevolentAI

Jackie has over thirty years of experience in the bioscience research sector, including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. 

More Posts

You Might Also Like

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022